As a GHS-R1a agonist, Ipamorelin is used as a pharmacological research tool for studying ghrelin receptor biology. The ghrelin receptor is expressed in the pituitary gland, hypothalamus, hippocampus, and peripheral tissues including the heart and adipose tissue. Research using Ipamorelin has helped map the downstream signaling cascades activated by GHS-R1a, including calcium influx, protein kinase C activation, and MAPK pathway engagement.³

Ipamorelin's clean selectivity profile makes it preferred over ghrelin itself for mechanistic studies, because ghrelin has additional biological activities through non-GHS-R1a pathways that can confound experimental results.

Studies in animal models have investigated Ipamorelin's effects on body composition — specifically, the balance between lean mass and fat mass. In rodent models, chronic Ipamorelin administration increased lean body mass and reduced adiposity without affecting food intake. The body composition changes were attributed to GH-mediated stimulation of protein synthesis and lipolysis.⁴

Research has also explored Ipamorelin in combination with dietary restriction models to investigate whether GH secretagogue treatment preserves lean mass during caloric deficit.

Growth hormone plays an established role in bone metabolism, and Ipamorelin has been studied in bone density models. Research in ovariectomized rat models (a standard model for postmenopausal bone loss) showed that Ipamorelin treatment increased bone mineral content and improved bone strength parameters. The effects were associated with increased osteoblast activity and bone formation markers.⁵

The bone research is particularly relevant because it demonstrates that Ipamorelin-stimulated GH release is sufficient to produce downstream effects on target tissues — confirming that the pulsatile GH release pattern achieves biological activity.

Ipamorelin is frequently studied in combination with growth hormone releasing hormone (GHRH) analogs like CJC-1295 (available as CJC NO DAC/Ipamorelin Blend in the OSYRIS catalog). The rationale for combination research is that GHRH and GHRP act through complementary mechanisms: GHRH stimulates GH synthesis and release from the pituitary, while GHRP (like Ipamorelin) amplifies the release signal. In animal models, the combination has produced greater GH output than either compound alone.⁶